Based on the extracted data from patients with (n = 14) and without a germline or somatic MEN1 mutation (n = 30) with at least one tumor with aberrant nuclear menin staining, we calculated the PPV and NPV for MEN1 syndrome diagnosis to be 80% (95% CI: 56-94) and 100% (95% CI: 87-100), respectively.18 However, it should be considered that our institution is a center of expertise for MEN1 syndrome and is, therefore, a center with a high prevalence of MEN1-related tumors. This evidence concerns the gene MEN1 and multiple endocrine neoplasia type 1.